The Company develops, manufactures and sells a complete line of reagents and automated systems used by hospitals, clinical laboratories and blood banks in tests performed to detect and identify certain properties of human blood.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Siding with tenmiles and others on the positive financial aspects of this company. Also the recent sell off and 15% drop open up an even better buying window.
BLUD was hit hard by the DOJ investigation and then hit again in June by the FDA threatening to revoke their ability to sell their blood reagents. I think that the market over reacted to the FDA news on top already low prices. BLUD says they have been working to fix the quality issues related to the FDA for some time now.